Cyclopam tablets

Indications

• Symptomatic relief of gastrointestinal disorders characterized by smooth muscle spasm
• Irritable bowel syndrome
• Acute spasm in diagnostic procedures

Dosage

Children: Child 12–17 years: 10–20 mg three times a day. Child 2–4 years: 5 mg three to four times a day. Child 1 month–1 year: 300–500 micrograms/kg three to four times a day (maximum per dose 5 mg).

Adults: 10–20 mg three times a day, increased if necessary up to 20 mg four times a day; maximum daily dose is 100 mg.

Mechanism of action

Dicycloverine hydrochloride functions as an antimuscarinic by blocking the action of acetylcholine at muscarinic receptors in the smooth muscles of the gastrointestinal tract. This inhibition results in reduced motility and relaxation of the gastrointestinal smooth muscle, alleviating spasms and cramping.

Pharmacodynamics

The primary effect of dicycloverine hydrochloride is the reduction of gut motility due to its antimuscarinic properties. It has a less pronounced antimuscarinic action compared to atropine but may also exhibit some direct relaxant effects on smooth muscle. This dual action helps in relieving abdominal pain associated with smooth muscle spasms.

Pharmacokinetics

Dicycloverine hydrochloride is well absorbed from the gastrointestinal tract. Its onset of action typically occurs within 30 minutes to 1 hour after oral administration, with a duration of effect lasting several hours. The drug undergoes hepatic metabolism and has a variable elimination half-life. Its clearance may be affected by renal function, and caution is advised in patients with renal impairment.

Contra-indications

• Hypersensitivity to dicycloverine or any of its components
• Glaucoma
• Myasthenia gravis
• Severe ulcerative colitis
• Obstructive uropathy
• Severe gastrointestinal obstruction

Adverse effects

• Dry mouth
• Dizziness
• Constipation
• Drowsiness
• Nausea
• Blurred vision
• Urinary retention
• Increased heart rate
• Skin reactions (e.g., flushing, urticaria)

Interactions

• Anticholinergic drugs may enhance effects
• Potentiation of the effects of other CNS depressants such as alcohol
• Antacids containing aluminium may increase risk of toxicity

Precautions

• Use with caution in patients with renal impairment
• May exacerbate conditions like glaucoma and myasthenia gravis
• Monitor for signs of anticholinergic syndrome

Pregnancy

Not known to be harmful; manufacturer advises use only if essential.

Breast-feeding

Avoid; present in milk with potential for causing apnoea in infants.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral solution: Dicycloverine hydrochloride 500 micrograms per 1 ml
• Combination products containing aluminium hydroxide and simeticone

Indications

• Mild to moderate pain
• Fever
• Headaches
• Muscle aches
• Arthritis
• Backaches
• Toothaches
• Colds

Dosage

Adults: For adults, the typical dosage is 500 mg to 1 g every 4 to 6 hours, with a maximum daily limit of 4 g. In cases of intravenous administration, the dosage is 15 mg/kg every

Mechanism of action

Paracetamol is thought to exert its analgesic effects by inhibiting cyclo-oxygenase (COX) enzymes, specifically COX-1 and COX-2, which are involved in the synthesis of prostaglandins responsible for pain sensation. Unlike most NSAIDs, paracetamol does not exhibit peripheral anti-inflammatory effects. Its antipyretic action is believed to result from direct action on heat-regulating centers in the brain, leading to peripheral vasodilation and sweating.

Pharmacodynamics

Paracetamol has been shown to have both antipyretic and analgesic effects, lacking any significant anti-inflammatory activity. It does not interfere with platelet aggregation or disrupt hemostasis, making it a safer option for individuals at risk of bleeding. Allergic reactions to paracetamol are rare. The drug does not affect uric acid secretion or acid-base balance when used at recommended doses.

Pharmacokinetics

Paracetamol is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 30 to 60 minutes after oral administration. It is primarily metabolized in the liver via conjugation with glucuronide and sulfate, with a minor pathway involving cytochrome P450 enzymes. The elimination half-life ranges from 1 to 4 hours, with renal excretion of metabolites as the primary route of elimination.

Adverse effects

• Nausea and vomiting
• Liver injury
• Renal damage
• Hypersensitivity reactions
• Flushing
• Hypotension
• Anorectal erythema
• Angioedema
• Agranulocytosis
• Thrombocytopenia
• Leukopenia
• Severe cutaneous adverse reactions (SCARs)

Interactions

• Increased risk of methaemoglobinaemia with topical prilocaine
• Increased risk of methaemoglobinaemia with topical anaesthetics
• Increased anticoagulant effect with coumarins
• Increased risk of hepatotoxicity with imatinib
• Decreased exposure with rifampicin
• Decreased exposure with pitolisant

Precautions

• Monitor patients with liver disease or heavy alcohol use for increased risk of hepatotoxicity
• Adjust doses in patients taking enzyme-inducing antiepileptic medications
• Use caution in patients with renal impairment
• Clinical judgement is required for dose adjustment in weight-based dosing

Pregnancy

Paracetamol is generally considered safe to use during pregnancy for pain and fever relief, but should be used at the lowest effective dose for the shortest duration necessary.

Breast-feeding

Paracetamol is excreted in breast milk in small amounts and is considered safe for use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets (500 mg)
• Oral suspension (120 mg/5 mL, 500 mg/5 mL)
• Rectal suppositories (various strengths)
• Intravenous infusion (various strengths)

Indications

• Irritable bowel syndrome (IBS)
• Gastrointestinal spasm
• Abdominal cramping

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: 20 mg to 40 mg orally, 4 times daily or 10 mg to 20 mg by intramuscular injection, as needed. Do not administer intravenously.

Mechanism of action

Dicyclomine achieves its action partially through direct antimuscarinic activity at the M1, M3, and M2 receptors, and partially through antagonism of bradykinin and histamine. It non-competitively inhibits the action of bradykinin and histamine, leading to a direct relaxant effect on smooth muscle, specifically reducing the strength of contractions observed in ileal spasms. Its major action appears to be a nonspecific direct relaxant effect on smooth muscle rather than competitive antagonism of acetylcholine.

Pharmacodynamics

Dicyclomine is classified as an anticholinergic agent that relaxes the smooth muscles of the intestines. Its duration of action is relatively short, leading to a typical administration schedule of four times daily, with doses ranging from 20-40 mg orally or 10-20 mg via intramuscular injection. It is important to note that dicyclomine should not be administered intravenously.

Pharmacokinetics

Dicyclomine is absorbed through the gastrointestinal tract and metabolized in the liver. The onset of action occurs within 1 hour of administration, with peak effects seen at approximately 1-2 hours. The elimination half-life varies, but it is generally in the range of 1-2 hours, necessitating multiple daily doses to maintain therapeutic levels. The drug is primarily excreted in urine as metabolites.

Contra-indications

• Glaucoma
• Myasthenia gravis
• Severe ulcerative colitis
• Obstructive uropathy
• Obstructive gastrointestinal disease
• Tachyarrhythmias

Adverse effects

• Dizziness
• Dry mouth
• Nausea
• Vomiting
• Constipation
• Blurred vision
• Tachycardia
• Urinary retention

Interactions

• Clozapine (unknown additive effect)
• Second-generation antipsychotics (unknown additive effect)

Precautions

• Use with caution in patients with renal impairment
• Use with caution in patients with hepatic impairment
• Caution in elderly patients due to increased risk of sensitivity to anticholinergic effects

Pregnancy

Dicyclomine is not recommended during pregnancy due to potential risk to the fetus.

Breast-feeding

Dicyclomine is excreted in breast milk and may cause adverse effects in nursing infants; use with caution.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablet (20 mg, 40 mg)
• Injection (10 mg, 20 mg)

Mechanism of action

Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine. Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum. ...MAJOR ACTION APPEARS TO BE NONSPECIFIC DIRECT RELAXANT ACTION ON SMOOTH MUSLCE RATHER THAN COMPETITIVE ANTAGONISM OF ACH.

Pharmacodynamics

Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines. It's duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection. Dicyclomine should not be administered intravenously.

Mechanism of action

According to its FDA labeling, acetaminophen's exact mechanism of action has not been fully established - despite this, it is often categorized alongside NSAIDs (non-steroidal anti-inflammatory drugs) due to its ability to inhibit the cyclo-oxygenase (COX) pathways. It is thought to exert central actions which ultimately lead to the alleviation of pain symptoms. One theory is that acetaminophen increases the pain threshold by inhibiting two isoforms of cyclo-oxygenase, COX-1 and COX-2, which are involved in prostaglandin (PG) synthesis. Prostaglandins are responsible for eliciting pain sensations. Acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, therefore, has no peripheral anti-inflammatory effects. Though acetylsalicylic acid (aspirin) is an irreversible inhibitor of COX and directly blocks the active site of this enzyme, studies have shown that acetaminophen (paracetamol) blocks COX indirectly. Studies also suggest that acetaminophen selectively blocks a variant type of the COX enzyme that is unique from the known variants COX-1 and COX-2. This enzyme has been referred to as _COX-3_. The antipyretic actions of acetaminophen are likely attributed to direct action on heat-regulating centers in the brain, resulting in peripheral vasodilation, sweating, and loss of body heat. The exact mechanism of action of this drug is not fully understood at this time, but future research may contribute to deeper knowledge. Although further investigation is warranted, the active metabolite of acetaminophen (AM404) was shown to interact with several molecular targets, including the Ca_v3.2 calcium channel, the cannabinoid CB1 receptors, TRPV1 receptors, and Na_v1.8 and Na_v1.7 channels. Acetaminophen produces analgesia and antipyresis by a mechanism similar to that of salicylates. Unlike salicylates, however, acetaminophen does not have uricosuric activity. There is some evidence that acetaminophen has weak anti-inflammatory activity in some nonrheumatoid conditions (e.g., in patients who have had oral surgery). ... Acetaminophen lowers body temperature in patients with fever but rarely lowers normal body temperature. The drug acts on the hypothalamus to produce antipyresis; heat dissipation is increased as a result of vasodilation and increased peripheral blood flow. The effects of acetaminophen on cyclooxygenase activity have not been fully determined. Acetaminophen is a weak, reversible, isoform-nonspecific cyclooxygenase inhibitor at dosages of 1 g daily. The inhibitory effect of acetaminophen on cyclooxygenase-1 is limited, and the drug does not inhibit platelet function. Therapeutic doses of acetaminophen appear to have little effect on cardiovascular and respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing. Acetaminophen (N-acetyl-p-aminophenol (APAP)) is the most common antipyretic/analgesic medicine worldwide. If APAP is overdosed, its metabolite, N-acetyl-p-benzo-quinoneimine (NAPQI), causes liver damage. However, epidemiological evidence has associated previous use of therapeutic APAP doses with the risk of chronic obstructive pulmonary disease (COPD) and asthma. The transient receptor potential ankyrin-1 (TRPA1) channel is expressed by peptidergic primary sensory neurons. Because NAPQI, like other TRPA1 activators, is an electrophilic molecule, /the researchers/ hypothesized that APAP, via NAPQI, stimulates TRPA1, thus causing airway neurogenic inflammation. NAPQI selectively excites human recombinant and native (neuroblastoma cells) TRPA1. TRPA1 activation by NAPQI releases proinflammatory neuropeptides (substance P and calcitonin gene-related peptide) from sensory nerve terminals in rodent airways, thereby causing neurogenic edema and neutrophilia. Single or repeated administration of therapeutic (15-60 mg/kg) APAP doses to mice produces detectable levels of NAPQI in the lung, and increases neutrophil numbers, myeloperoxidase

Pharmacodynamics

Animal and clinical studies have determined that acetaminophen has both antipyretic and analgesic effects. This drug has been shown to lack anti-inflammatory effects. As opposed to the _salicylate_ drug class, acetaminophen does not disrupt tubular secretion of uric acid and does not affect acid-base balance if taken at the recommended doses. Acetaminophen does not disrupt hemostasis and does not have inhibitory activities against platelet aggregation. Allergic reactions are rare occurrences following acetaminophen use.